Community Research documents how peptide practices develop outside formal trials. Reported schedules are presented as observations, not recommendations, and are kept separate from clinically studied regimens.
Tesamorelin is the evidence-rich counterpart to the rest of this series. Where BPC-157 and MOTS-c have little or no human data, tesamorelin is an FDA-approved drug with a defined regimen and substantial clinical evidence — but for a specific medical condition, not the body-composition goal most community users are chasing. That makes it an ideal case for a direct comparison: a genuine clinical regimen on one side, an off-label adaptation on the other. We’ve covered tesamorelin’s body-composition trial data in its own article; here we set the label beside the practice.
What it is
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). Like CJC-1295, it prompts the pituitary to release growth hormone in a way that preserves the body’s pulsatile pattern, raising GH and IGF-1. Its best-documented effect is a reduction in visceral adipose tissue — the deep abdominal fat around the organs — which is precisely why it drew interest beyond its approved population.
What formal research has actually studied
This is the strongest formal record in the series. Tesamorelin (brand name Egrifta) is FDA-approved to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy, and the approved regimen is specific: 2 mg subcutaneously once daily, injected into the abdomen. A newer formulation, Egrifta WR, is administered at 1.28 mg once daily for the same indication. In its registration program, participants receiving tesamorelin experienced an approximately 15% reduction in visceral adipose tissue from baseline over 26 weeks, significantly more than the placebo groups — a real, measured effect in the studied population.
Two boundaries matter. First, that evidence is in people with HIV-associated lipodystrophy; the drug’s efficacy and safety were established in that context, not in healthy adults using it for general fat loss or physique goals. Second, the visceral-fat reduction tends to reverse when the drug is stopped, and the label carries specific warnings and monitoring requirements. So the formal record is strong and bounded — a defined benefit, in a defined population, under a defined regimen.
What the community reports
Community use adapts that approved regimen toward a different objective — leanness and body composition in people without the approved condition. The figures below are drawn from commonly circulated community and vendor “research” guides available as of July 2026. They are community-reported conventions, not validated regimens or recommendations.
Across the community and vendor guides reviewed for this article, off-label use most often mirrors or modifies the clinical dose: commonly 1–2 mg per day subcutaneously, frequently started at around 1 mg in the evening to gauge tolerance; some community reports describe higher amounts in the 2–5 mg/day range. Evening or pre-bed timing is one of the most frequently repeated conventions, on the rationale of aligning with the natural nocturnal GH surge. Cycles are commonly described as twelve to twenty-six weeks on followed by four-to-eight-week breaks. Community patterns were reviewed across publicly accessible discussion and vendor materials available in July 2026; repetition is documented here as a convention, not treated as evidence of effectiveness.
| Reported convention | Apparent origin | Evidentiary status |
|---|---|---|
| ~1–2 mg/day subcutaneously | Mirrors the approved 2 mg clinical dose | Approved regimen, but for HIV lipodystrophy — not for general body composition |
| Higher 2–5 mg/day (some community reports) | Community convention | Above the studied dose; efficacy and safety not established |
| Evening / pre-bed timing | Rationale: aligning with the nocturnal GH surge | Plausible; not established as superior by comparative trials |
| 12–26 week cycles, then a break | Loosely mirrors trial durations | No validated off-label cycle length |
Where those conventions came from
Tesamorelin’s conventions are unusual because they have a real anchor: an actual approved dose and published trials. The 1–2 mg figure and the ~26-week horizon clearly borrow from the clinical regimen and trial length — this is a rare case where community practice is calibrated to genuine human data rather than to mouse studies or pure repetition.
But the borrowing is partial, and the gaps are where the caution lives. The approved evidence is for visceral fat in HIV-associated lipodystrophy; extending it to healthy users chasing general leanness is an off-label leap the trials do not cover. And the higher-than-label 2–5 mg range is pure convention — above the studied dose, with efficacy and safety at those amounts simply unestablished. A practice can be anchored to real data and still drift beyond what that data actually shows.
What remains unknown
The specific unknowns follow from that drift. Whether tesamorelin’s visceral-fat effect translates into the physique outcomes healthy users want, at the doses they use, is not established. The safety of long-term GH-axis elevation in people without the approved condition is not well characterized, and above-label dosing is uncharted. Because the effect reverses on cessation, the durability of any benefit is a real question.
And the usual measurement caveat applies to any non-pharmacy supply: community figures assume the vial holds what the label says, and a vial labeled 5 mg that tests at 4.3 mg makes label-based concentration estimates about 14% high — a net-content issue distinct from purity, as a certificate of analysis makes clear when purity and net content are read as separate questions.
Regulatory and sports context
Tesamorelin’s regulatory status is the cleanest in the series and the most easily misread. It is FDA-approved — but specifically for excess visceral abdominal fat in adults with HIV-associated lipodystrophy, at the labeled dose. Use for general fat loss or physique enhancement in people without that condition is off-label, and the pharmaceutical product is a different article from research-chemical tesamorelin sold for “research use only,” which carries no such manufacturing assurances.
In sport, tesamorelin is prohibited at all times by WADA under category S2 as a GHRH analog, in the same group as CJC-1295 and sermorelin. Athletes subject to testing would need to address any medically necessary use through the applicable Therapeutic Use Exemption process.
Why it matters
Tesamorelin shows the opposite pole of the series: a peptide where real human evidence exists, and where the interesting gap is not evidence-versus-nothing but approved-use-versus-off-label-use. That distinction is subtler and easier to blur than an outright absence of data — an approval can lend a borrowed authority to uses it never covered. Reading tesamorelin accurately means giving full weight to its genuine clinical record while keeping a bright line around what that record does and does not establish.